Clinical Trial Update: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update detailing a treatment plan for a recurrent uterine papillary serous carcinoma with a PIK3CA mutation; phases 2 and 3 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cancer
• Uterine Papillary Serous Carcinoma

Snippet

Sponsor: Greater Baltimore Medical Center | Conditions: Uterine Cancer | Phase 2, Phase 3 | Status: COMPLETED